LIVACOR Trial: Minimally Invasive LIVer And Simultaneous COlorectal Resection

Summary

The LIVACOR - Trial is a European wide, randomized controlled, open-label, multicenter trial. Patients with synchronous colorectal liver metastases (CRLMs) and primary colorectal tumor are considered eligible and will be randomized between minimally invasive (MI) combined or staged colorectal resection (all colectomies, including high anterior resection) and liver resection of up to three segments.

Conditions

• Colorectal Neoplasms Malignant
• Neoplasm Metastasis

Interventions

PROCEDURE

Minimally invasive simultaneous resection

One minimally invasive surgical procedure wherein both the primary colorectal carcinoma and the liver metastases are removed.

PROCEDURE

Minimally invasive two-stage resection

Two minimally invasive surgical procedures wherein the primary colorectal carcinoma and the liver metastases are removed

Sponsors & Collaborators

• Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

  collaborator OTHER

• University Hospital Southampton NHS Foundation Trust

  collaborator OTHER

• University Hospital Birmingham NHS Foundation Trust

  collaborator OTHER

• Liverpool University Hospitals NHS Foundation Trust

  collaborator OTHER_GOV

• King's College Hospital NHS Trust

  collaborator OTHER

• Manchester University NHS Foundation Trust

  collaborator OTHER_GOV

• Newcastle-upon-Tyne Hospitals NHS Trust

  collaborator OTHER

• University Hospital Plymouth NHS Trust

  collaborator OTHER

• Mauriziano Umberto I Hospital

  collaborator OTHER

• University Hospital Padova

  collaborator OTHER

• Fondazione Policlinico Universitario Agostino Gemelli IRCCS

  collaborator OTHER

• San Raffaele University Hospital, Italy

  collaborator OTHER

• Ospedali Riuniti Ancona

  collaborator OTHER

• Azienda Usl di Bologna

  collaborator OTHER_GOV

• Azienda Ospedaliero-Universitaria di Modena

  collaborator OTHER

• Federico II University

  collaborator OTHER

• Parma University Hospital

  collaborator OTHER

• Klinikum Saarbrücken, Klinik für Allgemein-, Viszeral- und Thoraxchirurgie, Chirurgische Onkologie

  collaborator OTHER

• Maastricht University Medical Center

  collaborator OTHER

• University of Navarrra Hospital (Clinica Universitaria)

  collaborator OTHER

• Hospital del Mar

  collaborator OTHER

• Assistance Publique - Hôpitaux de Paris

  collaborator OTHER

• Oslo University Hospital

  collaborator OTHER

• Ziekenhuis Oost-Limburg

  collaborator OTHER

• General Hospital Groeninge

  collaborator OTHER

• Moscow Clinical Scientific Center

  collaborator OTHER

• Centre Hospitalier du Luxembourg

  collaborator OTHER

• Fondazione Poliambulanza Istituto Ospedaliero

  lead OTHER

Principal Investigators

• Professor Mohammed Abu Hilal, MD PhD · Fondazione Poliambulanza Istituto Ospedaliero

Study Design

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Model

PARALLEL

Eligibility

Min Age

18 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2021-08-06

Primary Completion

2023-09-01

Completion

2024-09-01

Countries

• Belgium
• France
• Germany
• Italy
• Luxembourg
• Netherlands
• Norway
• Russia
• Spain
• United Kingdom

Study Locations